Figure 2From: Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy Event-free survival (A) and overall survival (B) of 334 patients comparing ch14.18 consolidation (blue line), NB90 oral maintenance therapy (green line), and no consolidation (red line).Back to article page
